User Image Cart Icon 0 Search Image

Glp 1 Agonist

  1. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
  2. GLP-1 agonist to treat obesity and prevent Cardiovascular Disease: what have we achieved so far?
  3. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size
  4. Effects of the GLPโ€1 agonist Exendinโ€4 on intravenous ethanol selfโ€administration in mice
  5. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study
  6. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure andย โ€ฆ
  7. GLP-1 agonist treatment: implications for diabetic retinopathy screening
  8. The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKA/CREB pathway in a rat model of knee osteoarthritis
  9. โ€ฆย of pentylenetetrazole-induced kindling and behavioral comorbidities in mice by levetiracetam combined with the GLP-1 agonist liraglutide: Involvement ofย โ€ฆ
  10. Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis
  11. Sustained release GLP-1 Agonist PT320 delays disease progression in a mouse model of Parkinsonโ€™s disease
  12. Efficacy of GLP-1 agonist therapy in autosomal dominant WFS1-related disorder: a case report
  13. SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM
  14. Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients
  15. Peptide oligomerization memory effects and their impact on the physical stability of the GLP-1 agonist liraglutide
  16. Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner
  17. Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice
  18. Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages
  19. Lixisenatide: a new daily GLP-1 agonist for type 2 diabetes management
  20. Neurochemical modulation involved in the beneficial effect of liraglutide, GLP-1 agonist on PTZ kindling epilepsy-induced comorbidities in mice
  21. Dulaglutide (Trulicity): the third once-weekly GLP-1 agonist
  22. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes atย โ€ฆ
  23. The evolving world of GLP-1 agonist therapies for type 2 diabetes
  24. (Val8)GLPโ€1โ€Gluโ€PAL: a GLPโ€1 Agonist That Improves Hippocampal Neurogenesis, Glucose Homeostasis, and ฮฒโ€Cell Function in Highโ€Fatโ€Fed Mice
  25. GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects
  26. Addition of SGLT2 inhibitor to GLPโ€1 agonist therapy in people with type 2 diabetes and suboptimal glycaemic control
  27. GLP-1 agonist Liraglutide prevents MKโ€‘801โ€“induced schizophreniaโ€‘like behaviors and BDNF, CREB, p-CREB, Trk-B expressions in the hippocampus and prefrontalย โ€ฆ
  28. Crystal structure of the GLP-1 receptor bound to a peptide agonist
  29. Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL/6J mice
  30. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
  31. Effects of GLP-1 agonist exenatide on cardiac diastolic function and vascular endothelial function in diabetic patients
  32. Rybelsus: an oral formulation of the GLPโ€1 agonist semaglutide
  33. Anticonvulsant effect of liraglutide, GLP-1 agonist by averting a change in GABA and brain glutathione level on picrotoxin-induced seizures
  34. Liraglutide: onceโ€daily GLPโ€1 agonist for the treatment of type 2 diabetes
  35. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimerโ€™s disease
  36. The impact of exenatide (a GLPโ€‘1 agonist) on markers of inflammation and oxidative stress in normal human astrocytes subjected to various glycemicย โ€ฆ
  37. Beneficial effects of GLP-1 agonist in a male with compulsive food-related behavior associated with autism
  38. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolicย โ€ฆ
  39. The GLP-1 agonist exendin-4 attenuates self-administration of sweetened fat on fixed and progressive ratio schedules of reinforcement in rats
  40. Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4
  41. Oral self-nanoemulsifying formulation of GLP-1 agonist peptide exendin-4: development, characterization and permeability assesment on Caco-2 cell monolayer
  42. A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products
  43. A GLPโ€1/glucagon (GCG)/CCK2 receptors triโ€agonist provides new therapy for obesity and diabetes
  44. Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats
  45. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway
  46. The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice
  47. The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy
  48. Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes
  49. Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: Aย โ€ฆ
  50. Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates
  51. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials
  52. MEDI0382, a GLPโ€1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a singleโ€dose, healthyโ€subject, randomized, phase 1 study
  53. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2ย โ€ฆ
  54. The novel GLPโ€1โ€gastrin dual agonist, ZP3022, increases ฮฒโ€cell mass and prevents diabetes in db/db mice
  55. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoEโˆ’/โˆ’ย โ€ฆ
  56. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: aย โ€ฆ
  57. The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouseย โ€ฆ
  58. Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update
  59. Role of renal sympathetic nerves in GLPโ€1 (glucagonโ€like peptideโ€1) receptor agonist exendinโ€4โ€mediated diuresis and natriuresis in dietโ€induced obese rats
  60. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes
  61. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes
  62. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model
  63. Adherence to GLP-1 agonist therapy in US managed care
  64. Acute pancreatitis during GLP-1 receptor agonist treatment. A case report
  65. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice
  66. Corrination of a GLP-1 receptor agonist for glycemic control without emesis
  67. The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats
  68. Factors associated with A1C reduction with GLP-1 agonist or SGLT-2 inhibitor use
  69. GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats
  70. Long-Acting Glucagon-Like Peptide-1 (GLP-1) Agonist Therapy in Post Solid Organ Transplant Patients.: Abstract# B913
  71. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations
  72. Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use
  73. The use of GLP-1 agonist therapy, liraglutide, is associated with significant weight loss in morbidly obese people without diabetes
  74. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obeseย โ€ฆ
  75. Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder
  76. Dapiglutide, a novel dual GLPโ€1 and GLPโ€2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel
  77. Semaglutide (GLPโ€1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceralย โ€ฆ
  78. Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent
  79. S2868 autoimmune hepatitis-like drug injury of the liver associated with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide
  80. Long-acting GLP-1 receptor agonist exenatide influence on the autonomic cardiac sympatho-vagal balance
  81. Effect of combined therapy of mesenchymal stem cells with GLP-1 receptor agonist, exenatide, on early-onset nephropathy induced in diabetic rats
  82. A GLP-1 receptor agonist inhibits aldosterone release in healthy volunteers
  83. GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state via GSK-3ฮฒ pathway
  84. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes
  85. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptyingโ€“preclinical evidence
  86. Lowest glucose variability and hypoglycemia are observed with the combination of a GLP-1 receptor agonist and basal insulin (VARIATION Study)
  87. Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide
  88. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes
  89. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weeklyย โ€ฆ
  90. Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBLย โ€ฆ
  91. The use of liraglutide, a GLP-1 agonist, in obese people with type 1 diabetes
  92. GSK2374697, a long duration glucagonโ€like peptideโ€1 (GLPโ€1) receptor agonist, reduces postprandial circulating endogenous total GLPโ€1 and peptide YY in healthyย โ€ฆ
  93. The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in miceย โ€ฆ
  94. IDF2022-1118 A comparative effect of DPP4 inhibitor and GLP-1 agonist on lipid profile among obese patients with DMT2
  95. Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP
  96. A novel antihypertensive effect of exenatide, a GLP-1 agonist
  97. Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects
  98. Combining SGLT2 inhibitor and GLP-1 agonist: exaggerated weight loss in a morbidly obese patient with type 2 diabetes
  99. Glucagon and a glucagonโ€GLPโ€1 dualโ€agonist increases cardiac performance with different metabolic effects in insulinโ€resistant hearts
  100. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placeboย โ€ฆ
  101. The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist
  102. Efficacy and safety of basal insulin/GLP-1 receptor agonist used in combination for type 2 diabetes management
  103. GLP-1 agonist use in a patient with an explainable cause of pancreatitis
  104. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascendingย โ€ฆ
  105. A hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist
  106. Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, singleย โ€ฆ
  107. Profound weight reduction with GLPโ€1 agonist therapy: a delayed hyperโ€response
  108. Major adverse cardiovascular events among patients with type-2 diabetes, a nationwide cohort study comparing primary metabolic and bariatric surgery toย โ€ฆ
  109. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinsonโ€™s disease by reducing chronic inflammation in the brain
  110. โ€ฆย Trial Investigators. Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants withย โ€ฆ
  111. Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampalย โ€ฆ
  112. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction andย โ€ฆ
  113. Separation of emetic and anorexic responses of exendin-4, a GLP-1 receptor agonist in Suncus murinus (house musk shrew)
  114. Exendin-4, a GLP-1 receptor agonist, interacts with proteins and their products of digestion to suppress food intake in rats
  115. Oral semaglutide: first-in-class oral GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus
  116. Systemic allergic reaction to the GLP-1 receptor agonist exenatide
  117. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes
  118. Tirzepatideโ€”a dual GIP/GLP-1 receptor agonistโ€”a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes
  119. The Efficacy of the GLP-1 Agonist Exenatide in the Treatment of Short Bowel Syndrome: 233
  120. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinsonโ€ฒ s disease by increasing expression of BNDF
  121. Glucagon-Like Peptide-1 (GLP-1) Agonist
  122. Treatment with semaglutide, a GLP-1 receptor agonist, improves extracellular matrix remodeling in the pancreatic islet of diet-induced obese mice
  123. Indices of betaโ€cell function: association with diabetes control in patients with type 2 diabetes on stable GLPโ€1 agonist treatment
  124. ACUTE PANCREATITIS AND TYPE 2 DIABETES MELLITUS: GLP-1 RECEPTOR AGONIST OR IDIOPATHIC, A DIAGNOSTIC DILEMMA, A CASE REPORT WITHย โ€ฆ
  125. PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinsonโ€™s Disease
  126. โ€ฆย Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants Withย โ€ฆ
  127. GLP-1 agonist protects myocardial hypoxia-reoxygenation injury through PI3K/Akt signaling pathway: an experimental study
  128. Drug-induced Liver Injury Associated with the Glucagon-like Peptide 1 (GLP-1) Agonist Liraglutide: 1131
  129. Hemochromatosis and cystic fibrosis carriers identify risk for GLP-1 agonist associated Pancreatitis
  130. Exendin-4, a GLP-1 receptor agonist, modulates the effect of macronutrients on food intake by rats
  131. Off target benefits of GLP-1 agonist therapy in type 2 diabetes
  132. 2136-PUB: GLP-1 agonist exendin-4 protects endothelial cells against hyperhomocysteinemia by alleviating ER stress and enhancing protein folding machinery
  133. Cellulitis at GLP-1 Agonist Injection Site: Rare But Relevant
  134. Off-label GLP-1 agonist treatment in 43 non-diabetic patients: are weight loss and treatment tolerance equally promising outside of clinical trials?
  135. The effect of the GLP-1 agonist, liraglutide, on the right ventricle in pulmonary hypertension
  136. Ozempicโ€“another GLP-1 agonist coming real soon
  137. The GLP-1 receptor agonist Exendin-4 modulates hippocampal NMDA-receptor signalling in aged rats and improves cognitive impairment in diabetic elderlyย โ€ฆ
  138. A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLPโ€1 dual agonist
  139. Sustained release subcutaneous delivery of BMS-686117, a GLP-1 receptor peptide agonist, via a zinc adduct
  140. Sglt-2 Inhibition Added to Glp-1 Agonist Therapy for Type 2 Diabetes: What is the Benefit?
  141. The use of GLP-1 agonist in an adolescent with type 1 diabetes mellitus and obesity
  142. Deaths stalk GLP-1 agonist
  143. GLP-1 agonist liraglutide increases metabolic-and cardiovascular-related sympathetic activity of the central nervous system.
  144. Tirzepatide. Dual GLP-1/GIP receptor agonist, Treatment of type 2 diabetes and obesity
  145. Experience of GLP-1 agonist Exenatide in the management of type 2 diabetic obese Pakistani patients
  146. Cardiovascular outcomes of SGLT-2 inhibitors and GLP-1 agonist based on race, ethnicity, and gender: A systematic review and meta-analysis of randomized trials
  147. Fixed-ratio combination of basal insulin and GLP-1 receptor agonist: is two better than one?
  148. USE OF GLP-1 AGONIST EXENATIDE TO TREAT REACTIVE HYPOGLYCEMIA AFTER GASTIC BYPASS SURGERY
  149. 1027-P: Lower Admission HbA1c Is Associated with Lower Likelihood of SGLT-2 Inhibitor or GLP-1 Agonist Prescription in Patients with Type 2 Diabetes afterย โ€ฆ
  150. Is there sustained weight loss after discontinuation of GLP-1 agonist for obesity treatment?
  151. The GLPโ€1 agonist liraglutide lowers blood pressure in a placental ischemic model of preeclampsia
  152. Combined GIP/GLP-1 Agonist: Safe for Type 2 Diabetes Patients?
  153. Nutritional insulin or Glp-1 receptor agonist: crossroads in the treatment of type 2 diabetes mellitus
  154. Pharmacotherapy for Weight Loss in Cirrhosis: A Case Series of GLP-1 Agonist-associated Weight Loss
  155. Effect of GLP-1 agonist Exenatide on cerebral, hepatic and peripheral glucose metabolism in postprandial state
  156. Effect of GLP-1 agonist on osteoblast proliferation and related signaling pathways
  157. 130-OR: The Association between High Out-of-Pocket Costs and Incidence of Treatment Intensification with an SGLT2 Inhibitor (SGLT2i) or GLP-1 Agonist (GLP-1a) inย โ€ฆ
  158. GLPโ€1 AGONIST LIRAGLUTIDE ACTIVATES METABOLICโ€AND CARDIOVASCULARโ€RELATED HYPOTHALAMIC NEURONS AND AUGMENTS REFLEXย โ€ฆ
  159. 4CPS-005 GLP-1 agonist liraglutide as add-on therapy in type 2 diabetes
  160. Liraglutide, GLP-1 receptor agonist, for chronic weight loss
  161. THE IMPACT OF GLUCAGON LIKE PEPTIDE-1 AGONIST THERAPY ON HEART RATE IN ADVANCED SYSTOLIC HEART FAILURE: AN ANALYSIS FROM THEย โ€ฆ
  162. Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: aย โ€ฆ
  163. 350-OR: A Novel Long-Acting GLP-1 Agonist (GL0034) Demonstrates Remarkable Efficacy on HbA1c, Weight Loss, and Triglycerides in a Model of Type 2 Diabetesย โ€ฆ
  164. Overcoming Therapeutic Inertia in Type 2 Diabetes: Combination GLP-1 Agonist and SGLT-2 Inhibitor Therapy Offers Hope
  165. GLP-1 Receptor Agonist Inhibited the Activation of RIPK1 for Alleviation the Neuronal Death and Neuroinflammation in APP/PS1 Mice
  166. Activity-Balanced GLP-1/GDF15 Dual Agonist to Treat Obesity in Mice and Non-Human Primates
  167. 1800-P: Cotadutide, a GLP-1/GCG Receptor Co-Agonist, Improves Insulin Sensitivity and Restores Normal Insulin Secretory Capacity in DIO Mice
  168. โ€ฆย Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants Withย โ€ฆ
  169. Meta-Analysis of GLP-1 Receptor Agonist Lixisenatide Use in Patients Insufficiently Controlled with Oral Antihyperglycemic Agents
  170. Could 99mTc labeled long-acting agonist of GLP-1 (Exendin-4) scintigraphy be a new tool in the diagnostics of unknown focus of insulinoma? preliminary results
  171. Diabetic cases controlled with low carbohydrate diet (LCD) and GLP-1 receptor agonist (GLP-1 RA)
  172. Hemodynamic effect of a single dose of glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide in patients with diabetic kidney disease.
  173. Evaluation of a combination of SGLT2 inhibitor and GLP-1 receptor agonist treatment in type 2 diabetes
  174. Reduction of Angiotensin II Induced Hypertension and Cardiac Fibrosis with GLP-1 Receptor Agonist and DPP-4 Inhibitor via Decreasing NADPH Oxidase Expression
  175. Potential role of GLP-1 receptor agonist in a rat model of cardio-renal syndrome type-3: effects on oxidative, inflammatory and inos expression axis
  176. Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes
  177. Master Thesis: EFFECT OF GLP-1 RECEPTOR AGONIST, EXERCISE, AND HIGH-FAT DIET ON VARIATION IN BODY WEIGHT, BLOOD GLUCOSE LEVELSย โ€ฆ
  178. Effects of glucagon-like peptide-1 receptor agonist (GLP-1RA) on cardiac structure and function: a systematic review and meta-analysis of randomized-controlled trials
Related Posts

Sedentary Lifestyle

BRASSINOSTEROIDS

Reversing Obesity

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping